Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report
oleh: Adeel Masood, Ahsan Wahab, Tanya Clifford, Eric J. Weaver, Hamid Ehsan, Walid El Ayass
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-12-01 |
Deskripsi
Abstract Secondary immune‐related hemophagocytic lymphohistiocytosis is a rare but life‐threatening complication of immune checkpoint inhibitors. HLH‐2004 and HLH‐1994 guidelines originally developed for primary HLH are the only available guidelines. It has proven to have a good prognosis if diagnosed promptly with discontinuation of immunotherapy and treated with corticosteroid monotherapy.